Detailed price information for Bioaffinity Technologies Inc (BIAF-Q) from The Globe and Mail including charting and trades.
Saliva molecular testing showed strong accuracy for pulmonary tuberculosis. Read more about this nonsputum diagnostic approach.
InvestorsHub on MSN
BioAffinity launches large-scale clinical study for lung cancer detection technology
Affinity Technologies (NASDAQ:BIAF) announced on March 10, 2026, the launch of a large longitudinal clinical study involving 2,000 patients to evaluate the performance of its CyPath® Lung technology ...
Detailed price information for Bioaffinity Technologies Inc (BIAF-Q) from The Globe and Mail including charting and trades.
Study to evaluate clinical performance of CyPath® Lung for the early detection of lung cancer in high-risk patientsMurtha Cancer Center Research Program at Uniformed Services University of the Health ...
Stocktwits on MSN
Why did BIAF stock surge 20% in pre-market today?
Shares of BioAffinity Technologies (BIAF) popped around 20% in pre-market trading on Tuesday, after the biotech company shared a positive update from a new case study evaluating its non-invasive ...
Substances capable of mutating human genetic material—altering and permanently damaging it—are present in many everyday products. Researchers at Justus Liebig University Giessen (JLU) have, for the ...
In a study published in Nature Medicine, researchers from the University of Oxford and the Muhimbili University of Health and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results